<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article114</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/DEFINITE" style="display:block; margin-bottom:10px;">DEFINITE Original</a></li>
<h2><strong>DEFINITE</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Mortality and Morbidity with an Implantable Cardioverter–Defibrillator in Patients with Nonischemic Dilated Cardiomyopathy".<br/>
The New England Journal of Medicine. 2004. 350(21):2151-2158.<br/>
PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Design<br/>
5 Population<br/>
5.1 Inclusion Criteria<br/>
5.2 Exclusion Criteria<br/>
5.3 Baseline Characteristics<br/>
6 Interventions<br/>
7 Outcomes<br/>
7.1 Primary Outcomes<br/>
7.2 Secondary Outcomes<br/>
8 Funding<br/>
9 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with nonischemic dilated cardiomyopathy, does prophylactic implantation of an implantable cardioverter–defibrillator (ICD) reduce the risk of sudden death from arrhythmia and overall mortality when added to standard medical therapy?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with nonischemic dilated cardiomyopathy and left ventricular dysfunction, the addition of an ICD to standard medical therapy including ACE inhibitors and beta-blockers resulted in a significant reduction in the risk of sudden death from arrhythmia and a nonsignificant reduction in overall mortality.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, randomized, controlled trial<br/>
- N=458 patients with nonischemic dilated cardiomyopathy<br/>
- Standard medical therapy (n=229) vs. standard medical therapy plus ICD (n=229)<br/>
- Mean follow-up: 29.0±14.4 months<br/>
- Analysis: Intention-to-treat<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Nonischemic dilated cardiomyopathy, left ventricular ejection fraction &lt;36%, presence of premature ventricular complexes or nonsustained ventricular tachycardia, symptoms of heart failure<br/>
- Exclusion Criteria: NYHA class IV heart failure, recent electrophysiological testing, permanent pacemakers, imminent cardiac transplantation, familial cardiomyopathies associated with sudden death, acute myocarditis, congenital heart disease<br/>
- Baseline Characteristics: Similar in both groups with mean left ventricular ejection fraction of 21%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were randomized to either standard medical therapy for heart failure, including ACE inhibitors and beta-blockers, or to the same therapy plus a single-chamber ICD.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcomes: Risk of death from any cause (hazard ratio with ICD, 0.65; 95% CI, 0.40 to 1.06; P=0.08)<br/>
- Secondary Outcomes: Sudden death from arrhythmia (hazard ratio with ICD, 0.20; 95% CI, 0.06 to 0.71; P=0.006)<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Funded by St. Jude Medical. Data collection and analysis independently performed at Northwestern University. Authors disclosed various relationships with medical device companies.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- Full text article available through the NEJM website
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
